

Grifols, S.A.

Avinguda de la Generalitat 152-158 08174 Sant Cugat del Vallès Barcelona - ESPAÑA

Tel. [34] 935 710 500 Fax [34] 935 710 267

www.grifols.com

Pursuant to the provisions of article 227 of the Law 6/2023, of 17 March, on Securities Markets and Investment Services, Grifols, S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

OTHER RELEVANT INFORMATION

Following the Inside Information communications published on 29 December 2023 with respect to Grifols and Haier Group Corporation ("Haier") having entered into a Strategic Alliance and Share Purchase Agreement to transfer approximately 20% of the shareholding in Shanghai RAAS Blood Products Co., Ltd. to Haier, Grifols reports that the period contractually established by the parties for the completion of the confirmatory due diligence by Haier has concluded with a satisfactory outcome.

Consequently, the closing of the transaction is now subject to obtaining the pending ordinary regulatory approvals.

As previously reported, the transaction is expected to close during the first half of the year 2024.

In Barcelona, on 1 March 2024

Nuria Martín Barnés Secretary to the Board of Directors